Compare Gilead Sciences, Inc. (GILD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Repligen Corporation Common Stock — how do they compare? Gilead Sciences, Inc. trades at $156 (market cap $190.38B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Gilead Sciences, Inc. is far larger — about 16.8× Repligen Corporation Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Repligen Corporation Common Stock for 0 Days on average.
| GILD | RGEN | |
|---|---|---|
Market Cap | $190.38B | $11.31B |
Volume | 5,758,183 | 1,216,919 |
Sector | Health | Health |
52-Week High | $155.80 | $194.57 |
52-Week Low | $117.85 | $102.87 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $11.20B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with strong analyst support (67% buy ratings) and a $153.13 consensus price target. Recent quarterly earnings beat expectations despite a Q2 loss, while revenue growth remains steady. Technical indicators show a bullish trend with support at $147-149 and resistance at $152-154. The company continues expanding HIV treatment access through recent PAHO partnerships.
GILD presents a mixed fundamental picture with strong revenue growth but negative net margins. The stock offers upside to analyst targets but faces execution risks in oncology pipeline development and competitive pressures. Recent institutional selling and high debt levels warrant monitoring, though expanding HIV franchise provides stable cash flow foundation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
